Novo Nordisk Outbids Pfizer in Metsera Acquisition Bid

Novo Nordisk offered $86.20 per share for Metsera, valuing the company at $10 billion.
Metsera's MET-097i is a mid-stage drug with once-monthly dosing and good tolerability.
Pfizer countered with $70 per share, valuing Metsera at $8.1 billion.
Pfizer filed lawsuits alleging anticompetitive conduct over MET-097i.
Novo Nordisk's bid could end the Pfizer-Metsera merger if Metsera's board prefers it.

Law | Business | Pharmaceuticals

United States | Denmark

2 days ago